FR2882264A1 - Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 - Google Patents

Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 Download PDF

Info

Publication number
FR2882264A1
FR2882264A1 FR0504942A FR0504942A FR2882264A1 FR 2882264 A1 FR2882264 A1 FR 2882264A1 FR 0504942 A FR0504942 A FR 0504942A FR 0504942 A FR0504942 A FR 0504942A FR 2882264 A1 FR2882264 A1 FR 2882264A1
Authority
FR
France
Prior art keywords
rimonabant
cannabinoid
administration
receptor antagonist
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR0504942A
Other languages
English (en)
French (fr)
Inventor
Corinne Hanotin
Pierre Rosenzweig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0501861A external-priority patent/FR2882261B1/fr
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to FR0504942A priority Critical patent/FR2882264A1/fr
Priority to FR0505228A priority patent/FR2882265B1/fr
Priority to KR1020077018993A priority patent/KR20070104913A/ko
Priority to MX2007009996A priority patent/MX2007009996A/es
Priority to JP2007555669A priority patent/JP2008530189A/ja
Priority to UY29386A priority patent/UY29386A1/es
Priority to EA200701781A priority patent/EA011618B1/ru
Priority to BRPI0608183-5A priority patent/BRPI0608183A2/pt
Priority to CA002597245A priority patent/CA2597245A1/fr
Priority to PCT/FR2006/000376 priority patent/WO2006087481A1/fr
Priority to AU2006215444A priority patent/AU2006215444A1/en
Priority to EP06709344A priority patent/EP1853264A1/fr
Priority to TW095105631A priority patent/TW200640457A/zh
Priority to ARP060100611A priority patent/AR053812A1/es
Publication of FR2882264A1 publication Critical patent/FR2882264A1/fr
Priority to TNP2007000297A priority patent/TNSN07297A1/en
Priority to US11/832,865 priority patent/US20080015229A1/en
Priority to CR9293A priority patent/CR9293A/es
Priority to IL185401A priority patent/IL185401A0/en
Priority to MA30158A priority patent/MA29262B1/fr
Priority to NO20074767A priority patent/NO20074767L/no
Priority to US12/402,988 priority patent/US20090197917A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0504942A 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2 Withdrawn FR2882264A1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR0504942A FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0505228A FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.
TW095105631A TW200640457A (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
PCT/FR2006/000376 WO2006087481A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
EP06709344A EP1853264A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
MX2007009996A MX2007009996A (es) 2005-02-21 2006-02-20 Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2.
JP2007555669A JP2008530189A (ja) 2005-02-21 2006-02-20 ２型糖尿病の防止および処置において使用することができる医薬品を調製するためのリモナバントの使用
UY29386A UY29386A1 (es) 2005-02-21 2006-02-20 Utilizción de rimonabant para la preparación de medicamentos útiles en la prevención y el tratamiento de la diabetes de tipo2.
EA200701781A EA011618B1 (ru) 2005-02-21 2006-02-20 Применение римонабанта для получения лекарственных средств, пригодных для профилактики и лечения диабета типа 2
BRPI0608183-5A BRPI0608183A2 (pt) 2005-02-21 2006-02-20 utilização do rimonabante para o preparo de medicamentos úteis na prevenção e no tratamento do diabetes do tipo 2
CA002597245A CA2597245A1 (fr) 2005-02-21 2006-02-20 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
KR1020077018993A KR20070104913A (ko) 2005-02-21 2006-02-20 2형 당뇨병의 예방 및 치료에 사용될 수 있는 약제의제조를 위한 리모나반트의 용도
AU2006215444A AU2006215444A1 (en) 2005-02-21 2006-02-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
ARP060100611A AR053812A1 (es) 2005-02-21 2006-02-21 Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo2
TNP2007000297A TNSN07297A1 (en) 2005-02-21 2007-07-31 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
US11/832,865 US20080015229A1 (en) 2005-02-21 2007-08-02 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes
CR9293A CR9293A (es) 2005-02-21 2007-08-07 Utilizacion de rimonabant para la preparacion de medicamentos utiles en la prevencion y el tratamiento de la diabetes de tipo 2
IL185401A IL185401A0 (en) 2005-02-21 2007-08-20 Use of rimonabant for the preparation of medicaments that can be used in the prevention and treatment of type 2 diabetes
MA30158A MA29262B1 (fr) 2005-02-21 2007-08-23 Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
NO20074767A NO20074767L (no) 2005-02-21 2007-09-18 Anvendelse av rimonabant for fremstilling av medikamenter som kan anvendes i forebygging og behandling av type 2 diabetes
US12/402,988 US20090197917A1 (en) 2005-02-21 2009-03-12 Use of rimonabant for the preparation of medicaments useful in the prevention and treatment of type 2 diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0501861A FR2882261B1 (fr) 2005-02-21 2005-02-21 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0504942A FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2

Publications (1)

Publication Number Publication Date
FR2882264A1 true FR2882264A1 (fr) 2006-08-25

Family

ID=36809538

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0504942A Withdrawn FR2882264A1 (fr) 2005-02-21 2005-05-12 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR0505228A Expired - Fee Related FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.

Family Applications After (1)

Application Number Title Priority Date Filing Date
FR0505228A Expired - Fee Related FR2882265B1 (fr) 2005-02-21 2005-05-23 Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2.

Country Status (10)

Country Link
JP (1) JP2008530189A (pt)
BR (1) BRPI0608183A2 (pt)
CR (1) CR9293A (pt)
EA (1) EA011618B1 (pt)
FR (2) FR2882264A1 (pt)
IL (1) IL185401A0 (pt)
MA (1) MA29262B1 (pt)
MX (1) MX2007009996A (pt)
TN (1) TNSN07297A1 (pt)
TW (1) TW200640457A (pt)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity

Also Published As

Publication number Publication date
FR2882265B1 (fr) 2009-02-13
EA011618B1 (ru) 2009-04-28
CR9293A (es) 2007-10-01
TNSN07297A1 (en) 2008-12-31
TW200640457A (en) 2006-12-01
JP2008530189A (ja) 2008-08-07
FR2882265A1 (fr) 2006-08-25
EA200701781A1 (ru) 2007-12-28
MA29262B1 (fr) 2008-02-01
IL185401A0 (en) 2008-08-07
BRPI0608183A2 (pt) 2009-11-17
MX2007009996A (es) 2007-10-10

Similar Documents

Publication Publication Date Title
EP1257275B1 (fr) Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
EP1795194A2 (fr) Utilisation d'un antagoniste des récepteurs CB1 associé à un bêta3-agoniste pour la préparation de médicaments utiles pour traiter l'appétence
JP2005533023A5 (pt)
US20070072907A1 (en) Use of a pyrazole derivative for preparing medicinal products that are useful in the prevention and treatment of dyslipidaemias and of diseases related to dyslipidaemias and/or to obesity
AU2011365756B2 (en) Antihypertensive pharmaceutical composition
NZ519231A (en) Use of nateglinide as an insulin secretion enhancer for treating impaired glucose metabolism
KR20050000546A (ko) 유기 화합물의 조합제제
DE602004012763T2 (de) Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker
FR2837706A1 (fr) Utilisation d'un antagoniste des recepteurs aux cannabinoides cb1 pour la preparation de medicaments utiles pour traiter les dysfonctionnements sexuels et/ou ameliorer les performances sexuelles
EP0429360B1 (fr) Inhibition du syndrome d'abstinence
FR2882261A1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR2882264A1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
CA2597245A1 (fr) Utilisation du rimonabant pour la preparation de medicaments utiles dans la prevention et le traitement du diabete du type 2
FR2882263A1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
FR2861301A1 (fr) Utilisation du derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
FR2882262A1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
FR2861302A1 (fr) Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique.
WO2008110697A2 (fr) Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
MXPA06004554A (en) Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity
FR2771006A1 (fr) Association de principes actifs pour le traitement de la demence senile du type alzheimer
KR20090075747A (ko) 부종의 발병을 예방, 지연 또는 감소시키기 위한 디펩티딜 펩티다제 ⅳ 억제제의 용도

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20070131